Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade

Protagonist Therapeutics, Inc. (NASDAQ:PTGX)’s stock price shot up 4.6% on Thursday after Citigroup raised their price target on the stock from $115.00 to $125.00. Citigroup currently has a buy rating on the stock. Protagonist Therapeutics traded as high as $101.43 and last traded at $101.5950. 187,169 shares traded hands during trading, a decline of 75% from the average session volume of 754,789 shares. The stock had previously closed at $97.09.

Other research analysts have also recently issued reports about the company. Truist Financial raised their target price on Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Barclays increased their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. The Goldman Sachs Group raised their price objective on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a “neutral” rating in a report on Tuesday, March 3rd. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday. Finally, TD Cowen upped their target price on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.54.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00. Following the completion of the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Asif Ali sold 46,203 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the completion of the sale, the chief financial officer owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 203,167 shares of company stock valued at $16,889,199. 4.90% of the stock is owned by insiders.

Key Headlines Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of ICOTYDE triggers a $50 million milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580 million in future milestones — a near-term cash boost and multi-year revenue upside. Access Newswire approval release
• Positive Sentiment: Wall Street commentary highlights that J&J’s FDA approval should create “significant value” for Protagonist by validating the IL‑23R oral-peptide approach and improving commercial prospects. MSN article
• Positive Sentiment: Citigroup raised its price target to $125 and maintained a Buy rating, signaling material upside (~22% from the cited reference price) and likely supporting investor demand. Benzinga note on Citi upgrade
• Positive Sentiment: Barclays increased its target to $119 and kept an Overweight rating, adding institutional endorsement of the approval’s commercial impact. Benzinga note on Barclays upgrade
• Neutral Sentiment: Industry coverage argues Protagonist’s first approval could pressure larger immunology incumbents — a thematic assessment that highlights competitive opportunity but does not change the company’s near-term revenue mechanics. BioSpace analysis
• Neutral Sentiment: Recent Seeking Alpha transcripts and slides from company/J&J commentary provide execution and commercialization details; useful for modeling royalty timing and market uptake but not immediate cash beyond the announced $50M. Seeking Alpha transcript slides
• Negative Sentiment: Protagonist’s recent quarterly results showed an EPS and revenue miss, large negative margins and no current product revenue — underscoring that most of the company’s value now rests on milestone/royalty receipts and future commercialization rather than recurring sales today. MarketBeat financial summary

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its stake in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new position in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $27,000. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the 3rd quarter worth approximately $62,000. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Stock Performance

The stock has a 50-day moving average of $86.37 and a 200 day moving average of $80.45. The firm has a market capitalization of $6.46 billion, a P/E ratio of -49.57 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. On average, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.